Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Relapsed Cancer

Dipenkumar ModiSmall moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

8 Active assets in the Relapsed Cancer cohort.

Asset / SponsorPhaseRating
Epirubicin
University Health Network, Toronto
Phase 2B
Cyclophosphamide
BeOne Medicines
Phase 2B
Eloxatin
BeOne Medicines
Phase 2CCC
PREDNISONE TABLETS
BeOne Medicines
Phase 2CCC
Inno-206
BeOne Medicines
Phase 2CCC
VINCRISTINE SULFATE
BeOne Medicines
Phase 2CCC
Cytosin-Arabinosid
Dipenkumar Modi
Phase 2CCC
FILGRASTIM
Anaveon AG
Phase 1C

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →